Clinical TrialsThe James Cancer Center Columbus, OH
open for enrollment
A Study to Test Combination Treatments in People With Advanced Non-Small Cell Lung Cancer
A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Subjects with Advanced Non-small Cell Lung Cancer (FRACTION-Lung)
The purpose of this study is to determine whether nivolumab in combination with other
therapies is more effective than nivolumab alone in people with advanced lung cancer.
Are you eligible?
Advanced Non Small Cell Lung Cancer (NSCLC)
Eastern Cooperative Oncology Group (ECOG) Performance status of ≤ 1
Life expectancy of at least 3 months from most recent chemotherapy or immunotherapy
Must have at least 1 lesion with measurable disease
Subjects with certain mutations that have not been treated with a targeted therapy
prior to enrollment
Subjects who need daily oxygen therapy
People with autoimmune disease